These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18393104)

  • 1. Sirtuins: novel targets for metabolic disease.
    Elliott PJ; Jirousek M
    Curr Opin Investig Drugs; 2008 Apr; 9(4):371-8. PubMed ID: 18393104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirtuins: novel targets for metabolic disease in drug development.
    Jiang WJ
    Biochem Biophys Res Commun; 2008 Aug; 373(3):341-4. PubMed ID: 18577374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirtuin activators.
    Alcaín FJ; Villalba JM
    Expert Opin Ther Pat; 2009 Apr; 19(4):403-14. PubMed ID: 19441923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic benefits from Sirt1 and Sirt1 activators.
    Chaudhary N; Pfluger PT
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):431-7. PubMed ID: 19474719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing metabolic disorders by novel SIRT1 activators.
    Sakamoto K
    Cell Metab; 2008 Jan; 7(1):3-4. PubMed ID: 18177718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases.
    Knutson MD; Leeuwenburgh C
    Nutr Rev; 2008 Oct; 66(10):591-6. PubMed ID: 18826454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.
    Lagouge M; Argmann C; Gerhart-Hines Z; Meziane H; Lerin C; Daussin F; Messadeq N; Milne J; Lambert P; Elliott P; Geny B; Laakso M; Puigserver P; Auwerx J
    Cell; 2006 Dec; 127(6):1109-22. PubMed ID: 17112576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirtuin activators and inhibitors.
    Villalba JM; Alcaín FJ
    Biofactors; 2012; 38(5):349-59. PubMed ID: 22730114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders.
    Huber K; Superti-Furga G
    Bioorg Med Chem; 2011 Jun; 19(12):3616-24. PubMed ID: 21306906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits?
    Timmers S; Hesselink MK; Schrauwen P
    Ann N Y Acad Sci; 2013 Jul; 1290():83-9. PubMed ID: 23855469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vino veritas: a tale of two sirt1s?
    Koo SH; Montminy M
    Cell; 2006 Dec; 127(6):1091-3. PubMed ID: 17174885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIRTUIN 1: regulating the regulator.
    Zschoernig B; Mahlknecht U
    Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective role of SIRT1 in diabetic vascular dysfunction.
    Orimo M; Minamino T; Miyauchi H; Tateno K; Okada S; Moriya J; Komuro I
    Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):889-94. PubMed ID: 19286634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can resveratrol help to maintain metabolic health?
    Schrauwen P; Timmers S
    Proc Nutr Soc; 2014 May; 73(2):271-7. PubMed ID: 24423148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1.
    Kelly G
    Altern Med Rev; 2010 Sep; 15(3):245-63. PubMed ID: 21155626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirtuin activators: designing molecules to extend life span.
    Camins A; Sureda FX; Junyent F; Verdaguer E; Folch J; Pelegri C; Vilaplana J; Beas-Zarate C; Pallàs M
    Biochim Biophys Acta; 2010; 1799(10-12):740-9. PubMed ID: 20601277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2.
    Kelly GS
    Altern Med Rev; 2010 Dec; 15(4):313-28. PubMed ID: 21194247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AROuSing SIRT1: identification of a novel endogenous SIRT1 activator.
    Verdin E
    Mol Cell; 2007 Nov; 28(3):354-6. PubMed ID: 17996699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seven sirtuins for seven deadly diseases of aging.
    Morris BJ
    Free Radic Biol Med; 2013 Mar; 56():133-71. PubMed ID: 23104101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slowing ageing by design: the rise of NAD
    Bonkowski MS; Sinclair DA
    Nat Rev Mol Cell Biol; 2016 Nov; 17(11):679-690. PubMed ID: 27552971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.